Curis, Inc. Announces Publication of Erivedge(TM) Data in The New England Journal of Medicine
LEXINGTON, Mass., June 7, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that two publications describing clinical data generated with Erivedge™ (vismodegib, GDC-0449) capsule were published in the current edition of The New England Journal of Medicine (NEJM).